Tools of Precision Medicine May Lead to Earlier Identification and Treatment of Children with Neurodevelopmental Disorders

Dec 9, 2015
Genetic mutations that explain why many children with congenital heart disease also have other significant health challenges
New York - 

Researchers from Columbia University Medical Center (CUMC), NewYork-Presbyterian, the Pediatric Cardiac Genetics Consortium, and the Pediatric Heart Network have found a number of genetic mutations that explain why many children with congenital heart disease also have other significant health challenges, including neurodevelopmental disorders and other congenital problems.

The study was published in the December 3rd online edition of Science.

About 10 percent of babies with congenital heart disease—which affects the development, structure, and function of the heart—are later diagnosed with neurodevelopmental disorders such as learning disabilities and attention-deficit hyperactivity disorder. As many as 13 percent of children with severe forms of congenital heart disease also have other types of birth defects.

One possible explanation is that children with congenital heart disease may be deprived of sufficient blood and oxygen flow during critical moments in brain development. The investigators explored the possibility that there is a more fundamental, genetic reason behind why neurodevelopmental disorders and congenital heart disease often occur together.

“Using the sophisticated tools of genomic sequencing, we can now look deep within the genome and determine if conditions are genetically linked,” said Wendy Chung, MD, PhD, the Kennedy Family Associate Professor of Pediatrics and Medicine, Director of the Clinical Genetics program at CUMC and a Clinical Geneticist at NewYork-Presbyterian/Columbia. “If such a linkage exists, then we can predict the risk that children with congenital heart disease will develop a neurodevelopmental disorder, allowing interventions to be put in place while the brain is still growing and developing. This kind of highly targeted treatment is the goal of an emerging field known as precision medicine.”

In this study, the researchers used genetic information from 1,213 children with congenital heart disease and their parents to analyze the 4,000+ genes that are active during heart development. They then compared this information with previously available sequence data from 900 families not affected by congenital heart disease, to identify genetic mutations.

The study revealed that many of the children with congenital heart disease had spontaneous mutations in heart development genes. Furthermore, a single genetic mutation was responsible for about 20 percent of cases of severe congenital heart disease accompanied by neurodevelopmental disorders and/or other congenital problems. These same genes were mutated in only 2 percent of children with congenital heart disease alone, suggesting that the co-occurrence of neurodevelopmental and congenital problems has genetic causes.

The researchers also discovered that the mutations in the children born with a combination of heart, brain, and other congenital disorders occurred in a subset of genes that act like conductors, orchestrating the formation and function of organs.

“As a clinical geneticist who sees children with a variety of conditions, I find it encouraging when a study has direct and immediate benefits for patients and their families,” said Dr. Chung. “We are seeing genomic sequencing move out of the realm of research and into the clinic as a diagnostic tool, bringing with it the power to predict the risk of many kinds of conditions. This is truly precision medicine at its best.”

The paper is titled, “De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies.”

The study was supported by grants from the National Institutes of Health (NIH), the National Heart, Lung, and Blood Institute, and the Pediatric Cardiac Genomics Consortium (U01-HL098188, U01-HL098147, U01-HL098153, U01-HL098163, U01-HL098123, U01-HL098162) as well as the Cardiovascular Development Consortium (U01-HL098166) and the National Human Genome Research Institute (U54HG006504) of the National Institutes of Health.

The researchers declare no financial or other conflicts of interest.

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.

NewYork-Presbyterian

NewYork-Presbyterian is one of the nation’s most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, ground-breaking research and clinical innovation.

NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine’s Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital’s ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.

NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 29,000 NewYork-Presbyterian professionals deliver exceptional care to more than 2 million patients.

Media Contact:

Public Affairs     212-821-0560     pr@nyp.org